![]() | ![]() |
Formats:
|
||||||||||||||||||||||||
Copyright © 2008 by the Genetics Society of America ADBP-1 Regulates an ADAR RNA-Editing Enzyme to Antagonize RNA-Interference-Mediated Gene Silencing in Caenorhabditis elegans *Department of Biology, Graduate School of Science, Kyushu University, Fukuoka 812-8581, Japan and †Department of Applied Life Science, Faculty of Biotechnology and Life Science, Sojo University, Kumamoto 860-0082, Japan 1Corresponding author: Department of Biology, Graduate School of Science, Kyushu University, 6-10-1, Hakozaki, Higashi-ku, Fukuoka 812-8581, Japan. E-mail: mfujiscb/at/mbox.nc.kyushu-u.ac.jp Communicating editor: M. Nonet Received June 30, 2008; Accepted July 22, 2008. This article has been cited by other articles in PMC.Abstract Small interfering RNAs (siRNAs) and microRNAs (miRNAs) mediate gene silencing through evolutionarily conserved pathways. In Caenorhabditis elegans, the siRNA/miRNA pathways are also known to affect transgene expression. To identify genes that regulate the efficiencies of the siRNA/miRNA pathways, we used the expression level of a transgene as an indicator of gene silencing and isolated a transgene-silencing mutant, adbp-1 (ADR-2 binding protein). The adbp-1 mutation caused transgene silencing in hypodermal and intestinal cells in a cell-autonomous manner, depending on the RNA interference (RNAi) machinery. The adbp-1 gene encodes a protein with no conserved domains that is localized in the nucleus. Yeast two-hybrid screening and co-immunoprecipitation analysis demonstrated that ADBP-1 physically interacts with ADR-2, an RNA-editing enzyme from the ADAR (adenosine deaminase acting on dsRNA) family. In the adbp-1 mutant, as previously shown in adr-2 mutants, A-to-I RNA editing was not detected, suggesting that ADBP-1 is required for the RNA-editing activity of ADR-2. We found that ADBP-1 facilitates the nuclear localization of ADR-2. ADBP-1 may regulate ADR-2 activity and the consequent RNA editing and thereby antagonize RNAi-mediated transgene silencing in C. elegans. RNA interference (RNAi) is an evolutionary conserved gene-silencing process. During RNAi, double-stranded RNA molecules (dsRNAs) are processed into ~21-nt small interfering RNAs (siRNAs) by the Dicer family of endoribonucleases. These small RNAs are incorporated into RNA-induced silencing complexes and guide the sequence-specific cleavage of complementary target RNAs (Ketting et al. 2001). RNAi can be elicited by exogenous dsRNAs supplied from outside the cell or by endogenous dsRNAs such as bidirectional transcripts and transcripts with extensive secondary structure. The RNAi-related gene-silencing mechanism is mediated by microRNAs (miRNAs), which are generated from short fold-back hairpin gene products. miRNAs are similar in length to siRNAs and regulate many important aspects of development and physiology in multicellular eukaryotes (Carthew 2006; Cerutti and Casas-Mollano 2006). Caenorhabditis elegans contains numerous siRNAs and miRNAs, suggesting that, by RNAi and related mechanisms, gene regulation occurs on a genomic scale (Ambros et al. 2003). These siRNAi/miRNA pathways are known to interact with each other in vivo, competing for shared components (Duchaine et al. 2006). Therefore, the changes in RNAi efficiency can influence the expression of a great number of genes, and the efficiency must be controlled precisely (Lee et al. 2006). RNAi has been shown to be involved in the protection of host genomes against invasion by repetitive sequences, such as viruses, transposons, and repetitive transgenes (Ketting et al. 1999; Li et al. 2002; Sarot et al. 2004; Robert et al. 2005). In the germline of C. elegans, expression of repetitive transgenes is repressed. This germline–transgene silencing process depends on some RNAi machinery genes, including mut-7, rde-2, and rde-3 (Tabara et al. 1999; Robert et al. 2005). It was demonstrated that the germline–transgene silencing is also mediated by chromatin proteins such as the Polycomb group of the transcriptional repressors MES-2 and MES-6 and their interacting protein, MES-4 (Kelly and Fire 1998; Fong et al. 2002). The transgene-silencing effect is less obvious in the somatic cells of C. elegans, although it can be induced in the RNAi-hyperactivated condition, such as in eri-1 and rrf-3 mutants (Simmer et al. 2002; Kim et al. 2005; Duchaine et al. 2006). The somatic transgene silencing is likely to be a similar process to the germline–transgene silencing because it also depends on mut-7 and mes-4 (Kim et al. 2005). It is predicted that dsRNAs are generated from aberrant transcripts of the repetitive transgenes and induce transgene silencing through RNAi and chromatin remodeling (Robert et al. 2005). The somatic transgene silencing is also induced by mutations of the ADAR (adenosine deaminases acting on dsRNA) genes, adr-1 and adr-2, in C. elegans. ADARs consist of a family of RNA-editing enzymes, which catalyze the hydrolytic deamination of adenosine to inosine in dsRNAs (A-to-I editing) and disrupt A–U pairs to create less stable I–U wobble pairs in dsRNAs (Wagner et al. 1989). It is likely that ADARs edit transgene-derived dsRNAs and thus antagonize RNAi of the transgene, resulting in the expression of the transgenes in wild-type C. elegans somatic cells (Knight and Bass 2002). Interestingly, in other species, ADARs have been also reported to antagonize the RNAi pathways (Nishikura 2006). For example, in Drosophila, dsRNAs that are excessively edited by ADARs become resistant to Dicer, resulting in reduced RNAi efficiency (Scadden and Smith 2001). Moreover, miRNA precursors can be edited by ADARs (Blow et al. 2006; Yang et al. 2006; Kawahara et al. 2007). The edited miRNA precursors are degraded by Tudor-SN, a ribonuclease specific for inosine-containing dsRNAs, and affect the developmental gene expression patterns (Yang et al. 2006). Here we report a new C. elegans mutant adbp-1, which was identified due to decreased expression levels of the transgenes in the somatic cells. adbp-1 encodes a novel protein that is localized in the nucleus. We found that ADBP-1 physically interacts with the ADAR protein ADR-2, facilitates the nuclear localization of ADR-2, and plays the crucial role for RNA editing. Our experimental results suggest that ADBP-1, acting together with an ADAR, controls the transgene expression by antagonizing the RNAi pathway. Furthermore, our results raise a possibility that ADBP-1 might restrict the RNA-editing activity to the nucleus and function for the target selection of RNA editing and RNAi. MATERIALS AND METHODS Strains and culture of C. elegans: Worms were grown on NGM plates seeded with an OP50 Escherichia coli strain using standard methods (Brenner 1974). The wild-type C. elegans strains used in this work were Bristol (N2) and CB4856. The following mutations were used in this work: LGII, adbp-1(qj1); LGIII, adr-2(ok735); LGIV, eri-1(mg366); and LGV, rde-1(ne219). We verified the mutation of adr-2(ok735), a deletion allele in which most of the coding region is deleted, by PCR. Mutant screening: Extrachromosomal simple arrays of lon-1p gfp and sra-6p gfp (as an injected marker) were integrated into a chromosome using UV irradiation, followed by outcrossing with N2 animals three times. The line carrying an integrated copy was mutagenized with 50 mm EMS. P0 worms were transferred to new plates and allowed to segregate self-progeny. The animals with reduced levels of lon-1p gfp expression were isolated from F2 synchronized worms at the L4 stage. Screening of ~12,000 haploid genomes yielded 10 candidate mutant lines. Because cross progenies with wild-type animals restored the normal lon-1p gfp expression level, the phenotype in all lines was not due to a change in the transgene but to a recessive mutation in the genome. Among the candidate mutant lines, we further analyzed the qj1 line, as the transgene-silencing phenotype was relatively strong compared to the other lines. None of the other lines failed to complement the qj1 locus.Quantitative RT–PCR: Trizol (Invitrogen) was used to prepare total RNA from worm pellets harvested from 1 liter of liquid culture. Poly(A)+ RNA was purified twice using an mRNA purification kit (GE Healthcare). First-strand cDNA was synthesized from poly(A)+ mRNA using a NotI d(T) 25 primer (5′-AACTGGAAGAATTCGCGGCCGCAGGAAT25-3′) and SuperScript III reverse transcriptase (Invitrogen). Quantitative PCR experiments were performed as described in the manual using SYBR Green PCR and RT–PCR reagents (Applied Biosystems) and a Gene Amp 5700 sequence detection system (Applied Biosystems). lon-1 mRNA levels were normalized to those of the act-1 mRNA. Genetic mapping and PCR fragment rescue of adbp-1 mutants: Genetic mapping was performed using the snip–SNP method (Wicks et al. 2001). PCR products used in the rescue experiments were amplified from wild-type genomic DNA. Germline transformations were performed according to the methods described previously (Mello et al. 1991). PCR product (20 ng/μl) was co-injected with ttx-3p mRFP marker DNA at 50 ng/μl into adbp-1(qj1) mutant animals.Plasmid construction: To construct lon-1p gfp, the predicted lon-1 promoter region (3.0-kb sequence upstream of lon-1) was cloned into the pPD95.77 GFP expression vector (a gift from A. Fire).To construct the GFP reporters of adbp-1, a genomic region containing the adbp-1 gene, the upstream gene VW02B12L.3 in the operon, and the 3.0 kb of upstream sequence was amplified from the Y70H7 YAC clone using PCR and ligated into pPD95.77. For promoter-gfp fusion, gfp was fused to the initiation codon of adbp-1. For translational gfp fusions, gfp was fused just before the termination codon of adbp-1. For the tissue-specific expression of adbp-1, full-length cDNA was obtained from the yk1745h09 EST clone (a gift from Yuji Kohara) and inserted into the pPD49.26 expression vector (a gift from A. Fire). The vha-7 promoter (for the main body hypodermis), the nhr-72 promoter (for seam cells), or the myo-2 promoter (for the pharynx) were inserted into the adbp-1 expression vector. Each promoter was obtained from N2 genomic DNA using PCRs (vha-7 and nhr-72) or by the digestion of pPD96.48 (myo-2). For the expression of adbp-1 in the nervous system, gfp was replaced with adbp-1 cDNA in the H20p gfp pan-neuronal gfp expression construct (Shioi et al. 2001).Two-hybrid screening: To construct a plasmid encoding the bait (pGBKT7-adbp-1) for the yeast two-hybrid screen, a full-length adbp-1 cDNA was obtained from yk1745h09 and inserted into the pGBKT7 vector (Clontech). Two-hybrid screens with ADBP-1 as the bait were performed in the Saccharomyces cerevisiae strain AH109. A C. elegans cDNA library (a gift from R. Barstead) was used for the screening. To screen for positive clones, the transformants were streaked onto the −Ade/−His/−Leu/−Trp plates and examined for the expression of the ADE2 and HIS3 reporters. RNA interference assay: RNAi clones were obtained from the C. elegans RNAi library (Geneservice). RNAi by feeding was performed as described previously (Timmons and Fire 1998). The following clones were used in this work: Geneservice ID I-3N01, I-5F19, II-7B03, II-7F12, III-4C08, III-5O20, and III-6N01. Cell culture, transfection, immunoprecipitation, and Western blotting: For the co-immunoprecipitation assays, Flag-tagged adbp-1 (ADBP-1 Flag) and Myc-tagged adr-2 (ADR-2 Myc) were expressed under the control of mammalian promoters. For the ADBP-1 Flag expression construct, the sequence encoding 3× Flag was fused to the 3′ terminus of full-length adbp-1 cDNA using a PCR-generated XbaI site and inserted into the pcDNA 3.1 Zeo(+) expression vector (Invitrogen). For the ADR-2 Myc expression construct, full-length adr-2 cDNA, obtained from the yk1255b05 EST clone (a gift from Yuji Kohara), was inserted into the pcDNA3.1/Myc-His expression vector (Invitrogen). To obtain stronger expression, the region encoding ADR-2 Myc was transferred to another expression vector, pCAGGS-2 (Niwa et al. 1991). HEK293T cells were cultured in D-MEM (Sigma) containing 10% fetal bovine serum. HEK293T cells were transfected with ADBP-1 Flag and/or ADR-2 Myc expression constructs using Lipofectamine 2000 (Invitrogen). After transfection, cells were cultured for 48 hr and whole-cell lysates were prepared using radio immunoprecipitation assay buffer containing complete mini protease inhibitor cocktail (Roche). The lysates were incubated with anti-Flag (Sigma) or anti-Myc antibodies (Invitrogen) and the immunocomplexes were collected with protein A–Sepharose CL-4B (GE Healthcare). The blotted membranes were incubated with anti-Myc (Invitrogen) or anti-Flag (Sigma) primary antibodies and anti-mouse IgG and HRP-linked whole secondary antibody from sheep (GE Healthcare) before visualization of the immunoreactive proteins using an ECL advanced Western blotting detection kit (GE Healthcare).Fluorescence intensity analysis of lon-1p gfp: The fluorescence images of L4-stage hermaphrodites harboring the Is[lon-1p gfp] transgene were captured with an Axioplan 2 microscope (Zeiss) equipped with an AxioCam CCD camera (Zeiss) using the same magnification and the same exposure time. These images were analyzed with the Image-Pro Plus image analysis program (Media Cybernetics). By using a line profile tool, the fluorescence intensities of the three body regions at the posterior end of the pharynx, the vulva, and the posterior end of the intestine were measured and averaged for the fluorescence intensity of the body of each animal. The score of each strain was the average measurement of 20–30 animals.Fluorescence intensity analysis of vha-7p adr-2 gfp: The fluorescence images of L4-stage hermaphrodites harboring the Ex[vha-7p adr-2 gfp] transgene were captured with a LSM 510 laser-scanning confocal microscope (Zeiss) using the same gain setting. These images were analyzed with the Image-Pro Plus image analysis program (Media Cybernetics). By using a line profile tool, the fluorescence intensities of the three nuclei and the three cytoplasmic regions near the nuclei were measured and averaged for the nucleic fluorescence intensity and the cytoplasmic fluorescence intensity of each animal. The scores of each strain were the average measurement of 19–24 animals.Chemotaxis assay: The chemotaxis assay was based on assays developed previously (Bargmann and Horvitz 1991; Bargmann et al. 1993). Odorant dilutions for the chemotaxis assays were as follows: diacetyl, 10−3 and 10−4; 2-butanone, 10−2 and 10−3; and benzaldehyde, 10−2, 10−3, and 10−4. Amplification and sequencing of ADAR substrates: cDNA was prepared as described above. cDNA corresponding to ADAR substrates (9A, 16G, 36A, and laminin-γ; Morse and Bass 1999; Morse et al. 2002) was amplified in two rounds of PCRs. PCR products were sequenced using the PCR primers from the second amplification. Primers: The primers used in this study were the following. For quantitative RT–PCR, act-1 sense primer (5′-GAGCACGGTATCGTCACCAA-3′); act-1 antisense primer (5′-TGTGATGCCAGATCTTCTCCAT-3′); lon-1 sense primer (5′-TTCTGACGCTATCTCGATCT-3′); lon-1 antisense primer (5′-CTTGGATTATGGACCTCGTT-3′); for plasmid construction, vha-7 sense primer (5′-AAAACTGCAGCGACAGGAAATTGTGAGAAG-3′); vha-7 antisense primer (5′-AAAACTGCAGCAGATTACGTCGTTGGTGGA-3′); nhr-72 sense primer (5′-TTTTCTGCAGCCTGCTCTGATACAGCTATC-3′); nhr-72 antisense primer (5′-TTTTCTGCAGGAGTGAAATTCGGCGACTCA-3′); for amplification of ADAR substrates—first PCR primer, 9A sense primer (5′-ATATCATCGATGCAGCTCGG-3′); 16G sense primer (5′-CGCTTTCGTTCCGAATCTTG-3′); 36A sense primer(5′-GTTTTCAAACCAGTGGAGCC-3′); laminin-γ sense primer (5′-GAGATTCCACCGAAGCTGTT-3′); oligo(dT) tagged sequence antisense primer (5′-TCGCGGCCGCAGGAA-3′); for amplification and sequencing of ADAR substrates—second PCR primer, 9A sense primer (5′-GGCACTTCAATTTGCACACC-3′); 9A antisense primer (5′-AAATGACCTAAAGGTGGTTA-3′); 16G sense primer (5′-ACGTGTGTGGACATTTACGG-3′); 16G antisense primer (5′-AAAGAAATATCTTCGTTTGC-3′); 36A sense primer (5′-AATGGATTCGGTGTCCGAAC-3′); 36A antisense primer (5′-ACAGGCTAAAAGCTCAGCAC-3′); laminin-γ sense primer (5′-AAATGGCTACTGAAGCGGTC-3′); laminin-γ antisense primer (5′-GAGATTCCACCGAAGCTGTT-3′). RESULTS Isolation of the transgene-silencing mutant adbp-1: To study the regulation of the siRNA/miRNA pathways in C. elegans, we screened for mutants that showed altered expression levels of repetitive transgenes. In C. elegans, injection of one or a few of DNA plasmids into the gonad results in formation of a highly repetitive transgene, referred to as a simple array because the injected DNA forms long tandemly arranged arrays (Stinchcomb et al. 1985). We used a simple array of a lon-1p gfp transgene as an indicator, which is a fusion of the lon-1 promoter and gfp. The lon-1p gfp transgene gives strong GFP expression in the main-body hypodermal cells (hyp 7 and some other hypodermal cells in the tail and head) and intestine of L1 larvae through adulthood, which enabled us to detect changes in the expression levels easily. First, we produced a transgenic worm stably expressing the lon-1p gfp transgene, which was integrated into one of the chromosomes. After mutagenizing the worms with ethyl methansulfonate (EMS), we isolated one mutant (qj1) that showed a significant reduction in the GFP level (Figure 1A
The lon-1 gene encodes a secreted protein with homology to members of the pathogenesis-related-protein superfamily, and mutations in lon-1 cause a long-body-size phenotype (Maduzia et al. 2002). If the adbp-1 mutation affected the expression of the endogenous lon-1 locus, the adbp-1(qj1) mutant should have exhibited the long-body phenotype. The mutant, however, did not show any obvious changes in its body length (data not shown). Furthermore, we quantified the level of lon-1 transcripts using quantitative RT–PCRs and found that the levels of lon-1 transcripts were similar in adbp-1(qj1) mutants and wild-type worms (Figure 1B The adbp-1 mutation induces silencing on various transgenes in the hypodermis and intestine: The silencing effect of adbp-1(qj1) was not limited to the integrated array of the lon-1p gfp transgene, because we observed a similar reduction of GFP expression from an extrachromosomal array of lon-1p gfp in the adbp-1(qj1) mutant (data not shown). Moreover, we examined whether other transgenes expressed in the hypodermis and intestine were also affected by the adbp-1 mutation. As shown in Figure 2 gfp transgene, which drives GFP expression in the main-body hypodermal cells. The expression of nhr-68p gfp, which drives GFP expression in the main-body hypodermal cells, the hypodermal seam cells, and the intestine, was also affected by the adbp-1 mutation; the GFP expression levels in all these tissues were reduced. Next, we examined transgenes expressed in other tissues. The expression levels of GFP in body-wall muscle and pharyngeal muscle, driven by myo-3p gfp and myo-2p gfp, respectively, were only mildly affected by the adbp-1 mutation. The expression of GFP in neuronal tissues driven by H20p gfp appeared to be unaffected by the adbp-1 mutation, although we did not closely examine the GFP expression levels in individual neurons. Taken together, the results show that the adbp-1 mutation affected the expression of various transgenes expressed in the hypodermis and intestine, although the adbp-1 mutation did not appear to markedly affect transgenes expressed in muscles and neurons.
Transgene silencing in the adbp-1 mutant depends on the repetitive context of the transgene: In C. elegans, transgenes are usually highly repetitive simple arrays, which are produced by injection of one or a few of DNA plasmids into animals. All the transgenes used in this study were the simple arrays unless noted. If the composition of the injected DNA is more complex, the resulting arrays are less repetitive and are referred to as complex arrays. To examine whether transgene silencing in adbp-1 mutant animals depended on the repetitive context of the simple arrays, we produced complex arrays by injecting nhr-68p gfp with an excess of other genomic DNA fragments. As mentioned above, the simple array of nhr-68p gfp was strongly silenced in the adbp-1(qj1) mutant. On the other hand, all three adbp-1(qj1) lines carrying the independent complex arrays of nhr-68p gfp showed strong GFP expression as was observed in wild-type animals (Figure 1CMolecular identification of adbp-1: The adbp-1 mutation was mapped to a small region (350 kb) on chromosome II between two SNP markers on the F37H8 and B0334 cosmids using standard SNP mapping methods. Because none of the cosmids in this region that we examined rescued the decreased lon-1p gfp expression in adbp-1 animals, eight genes located at the joints of the cosmid contigs were good candidates for the responsible gene. In an attempt to phenocopy the adbp-1 mutant, we conducted RNAi analyses using these eight genes. Strikingly, RNAi of the VW02B12L.4 gene caused a reduction in lon-1p gfp expression (Figure 3, A and B gfp expression in adbp-1 animals (Figure 3, A and C gfp expression in adbp-1 animals (Figure 3A
VW02B12L.4 gene encodes a 217-amino-acid protein with no conserved domains and no apparent nuclear localization signal. Sequencing of the VW02B12L.4 locus in the adbp-1(qj1) mutant revealed a nonsense mutation in the middle of the coding region (Q119STOP) (Figure 3D ADBP-1 localizes in nuclei throughout development: To analyze the expression of adbp-1, we made two GFP reporter constructs. One was a promoter-gfp fusion; gfp was fused with an ~4-kb genomic fragment containing the promoter region (~3 kb), an upstream gene in the operon, and the ATG initiation codon of adbp-1 (Figure 4A gfp expression in adbp-1(qj1) mutant animals (data not shown), endogenous adbp-1 is likely to be expressed in at least some of the tissues in which we observed GFP expression.
ADBP-1 functions in a cell-autonomous manner: adbp-1 is expressed in the hypodermis and other tissues. We then asked whether the expression of lon-1p gfp in the main-body hypodermal cells is controlled by ADBP-1 acting in the same cells. adbp-1 cDNA was fused to various promoters, which resulted in expression of the protein in various tissues, including the main-body hypodermal cells (vha-7 promoter), pharynx (myo-2 promoter), seam cells (nhr-72 promoter), and neurons (H20 pan-neuronal promoter). We introduced these constructs into adbp-1(qj1) mutant animals bearing an integrated array of lon-1p gfp. As shown in Figure 5 gfp in the main-body hypodermal cells. On the other hand, the adbp-1 constructs with the other promoters, whose expressions in the expected tissues were confirmed by fusing mRFP cDNA to the 3′-end of the adbp-1 cDNA (data not shown), did not restore the lon-1p gfp expression level (Figure 5 gfp transgene.
ADBP-1 interacts with ADR-2: To elucidate the molecular function of ADBP-1, we performed a yeast two-hybrid screen to identify interacting proteins. A screen of a C. elegans cDNA library yielded 10 positive clones when full-length ADBP-1 was used as the bait. Among these positive clones, two independent clones encoded N-terminal portions of the ADR-2 protein, indicating that ADR-2 was potentially interacting with ADBP-1. ADR-2 is one of the ADAR proteins, which are a family of RNA-editing enzymes in C. elegans (Tonkin et al. 2002). Interestingly, Li et al. (2004) also reported a possible interaction between ADR-2 and ADBP-1 in their systematic yeast two-hybrid analyses for the interactome map of C. elegans. To confirm this interaction, we performed co-immunoprecipitation experiments. We transiently expressed Flag-tagged ADBP-1 and Myc-tagged ADR-2 in HEK293T cells. Using the cell lysates, ADBP-1 was immunoprecipitated with anti-Flag antibodies. We found that ADR-2 specifically co-immunoprecipitated with ADBP-1 by immunoblotting with anti-Myc antibodies (Figure 6A
Genetic interactions between adbp-1 and adr-2: Interestingly, a mutation in the adr-2 gene has been reported to cause a transgene-silencing phenotype (Knight and Bass 2002). When the lon-1p gfp transgene was introduced into the adr-2(ok735) mutant strain, GFP expression decreased to a level similar to that observed in the adbp-1 mutant (Figure 6, B and CWe also examined whether adr-2 produced a similar tissue-specific transgene-silencing phenotype as was observed with adbp-1. When various gfp reporter constructs were introduced into the adr-2(ok735) mutant, we observed that adr-2 caused a marked reduction in GFP expression in the hypodermis and intestine, whereas only minor changes were detected for GFP expression in muscle and neurons (Figure 2 Because ADBP-1 and ADR-2 appeared to act together, we asked if the other phenotypes observed in the adr-2 mutant would also be present in the adbp-1 mutant. Because it has been reported that the adr-2 mutant is defective for chemotaxis (Tonkin et al. 2002), we analyzed the chemotactic responses of the adbp-1 animals. Although we assayed the animals with multiple odorants at various concentrations, we did not detect any significant defects in the adbp-1 mutants (Figure 7
RNAi processes mediate transgene silencing in adbp-1: The somatic transgene-silencing phenotype in the known mutants including adr-2, rrf-3, and eri-1 was suppressed by mutations in the RNAi machinery genes rde-1 and dcr-1, as consistent with the model that transgene silencing is caused through RNAi of the transgene (Kim et al. 2005). In the adbp-1 mutant, we found that a rde-1 mutation and RNAi of dcr-1 also restored the expression of lon-1p gfp (Figure 8, A–D
Knight and Bass (2002) demonstrated that transgene-derived dsRNAs were subject to A-to-I editing in wild-type animals and proposed a model in which ADR-2 edits transgene-derived dsRNAs and prevents RNAi of the transgene in wild-type animals. In the adr-2 mutant, unedited dsRNA may trigger RNAi of the transgene. In the adbp-1 mutant, RNAi-inducible dsRNA also appears to exist, because the transgene silencing in adbp-1 was mediated by the RNAi machinery. Knight and Bass (2002) used transgenes of simple arrays and predicted that aberrant transcripts from the sequences tandemly arranged in opposing orientations in the simple arrays may result in the formation of dsRNA. This is supported by our results, because all three independent nhr-68p gfp transgenes of complex arrays, which had less repetitive context, were not silenced in the adbp-1 mutant (Figure 1C gfp) and a complex array (nhr-68p gfp), both of which carried the same gfp gene (Figure 8, E–H gfp and nhr-68p gfp were directed to express, whereas in the seam cells only nhr-68p gfp was directed to express. Therefore, dsRNA is likely to suppress the transgene expression cell autonomously.The adr-2 and adbp-1 mutants did not show RNAi hypersensitivities even in the hypodermis: ADR-2 probably edits dsRNAs produced from transgenes and antagonizes RNAi of the transgenes. On the basis of the results of the physical interaction assays and the genetic analyses, we predicted that ADBP-1 acts together with ADR-2 in the process. We asked whether ADR-2 and ADBP-1 also antagonize RNAi induced by exogenously introduced dsRNAs. If this is the case, adbp-1 and adr-2 mutants may show RNAi-hypersensitive phenotypes. In a previous study, the adr-2 mutant showed no enhancement of RNAi induced by injection of dsRNA (Knight and Bass 2002). Since the previous analysis targeted mainly the unc-22 gene, which was expressed in the muscle, we intended to examine the RNAi hypersensitivity by targeting genes expressed in the hypodermis, where the transgene silencing was most obvious. For the RNAi targets, we chose four genes that are required for normal development or behavior and act in the hypodermis (hmr-1, bli-1, and bli-5) or the muscle (unc-15) (Table 1). We fed the worms E. coli that expressed dsRNA specific for the targeted genes. As expected, the RNAi-defective rde-1 mutant and the RNAi-hypersensitive eri-1 mutant showed lower and higher sensitivities to RNAi of each tested gene, respectively (Table 1). adr-2(ok735) and adbp-1(qj1) animals, however, showed only a small enhancement of hmr-1 RNAi and no significant changes in RNAi of other genes, compared to wild-type responses. Thus, ADR-2 and ADBP-1 do not appear to interfere with the siRNA pathway triggered by exogenous dsRNA even in the hypodermis.
ADBP-1 is required for the deaminase activity of ADR-2: Because ADBP-1 appeared to function with ADR-2, we hypothesized that ADBP-1 may be required for the deamination of adenosine by ADR-2. Although C. elegans has two ADAR homologs, ADR-1 and ADR-2, ADR-2 appears to play a major role in the deamination of adenosine because a deaminase activity was not detected in an adr-2 mutant, whereas a partial deaminase activity remained in an adr-1 mutant (Tonkin et al. 2002). In C. elegans, 10 ADAR substrates have been identified (Morse and Bass 1999; Morse et al. 2002); they are edited at stem-loop structures located in noncoding regions. We examined four of these ADAR substrates to test whether A-to-I editing occurred in the adbp-1 animals. We isolated poly(A)+ RNA from the adbp-1(qj1) mutant and wild-type animals and prepared cDNA. The RNA-editing sites were amplified in PCRs and the entire population of PCR products was directly sequenced. As previously reported, the results should correctly reflect the editing states of each substrate (Morse et al. 2002). Because inosine pairs with cytidine, inosine is represented by guanosine in the corresponding cDNA sequence. Sequencing electropherograms from wild-type cDNA showed that the A peaks (green in Figure 9A
ADBP-1 facilitates the nuclear localization of ADR-2: How does ADBP-1 control the deaminase activity of ADR-2? We analyzed the subcellular localization pattern of ADR-2 by expressing full-length adr-2 cDNA fused with gfp under the control of the hypodermal promoter (vha-7p adr-2 gfp). ADR-2 GFP accumulated in the nucleus and was also observed in the cytoplasm of hypodermal cells (Figure 9B adr-2 gfp transgene was reduced in the adbp-1 mutant, but the low-level expression of GFP observed at high magnification allowed us to examine the subcellular localization pattern. We found an apparent reduction of GFP fluorescence in the nucleus of the adbp-1 mutant; ADR-2 GFP was not accumulated in the nucleus, but distributed evenly in the nucleus and the cytoplasm (data not shown). This may not be simply due to the reduction of the GFP expression level because in another transgene-silencing mutant, eri-1, we observed the nuclear accumulation of ADR-2 GFP (data not shown). We further analyzed the ADR-2 GFP subcellular localization patterns by suppressing the transgene-silencing phenotype of the adbp-1 mutant by a rde-1 mutation. In the adbp-1(qj1);rde-1(ne219) double mutant, the expression level of ADR-2 GFP was comparable to those in wild-type and in rde-1(ne219) animals, but the nuclear accumulation was again less obvious than these control lines (Figure 9BDISCUSSION In this article, we identified ADBP-1, an ADAR-binding protein, in a genetic screen for mutations causing transgene silencing and found that it affects the siRNA pathway through RNA editing. Thus, our results demonstrate that the screen of transgene-silencing mutants is a successful way to identify the genes involved in the miRNA/siRNA pathways, as was shown in previous studies (Hsieh et al. 1999; Wang et al. 2005; Cui et al. 2006). ADBP-1 is required for RNA editing in C. elegans: In this study, we identified the novel protein ADBP-1, which plays a crucial role in RNA editing through binding to the RNA-editing enzyme ADR-2. ADR-2 is a major ADAR protein in C. elegans. RNA editing mediated by ADARs is an important biological process, because it creates diversity among the transcripts by recoding genes or changing characteristics of the transcripts, such as their stability (Nishikura 2006). We have shown that adbp-1 and adr-2 mutant animals exhibit similar tissue-specific, transgene-silencing phenotypes. Double-mutant analysis suggested that these genes function in the same genetic pathway. By using co-immunoprecipitation analysis, we have demonstrated that ADBP-1 directly interacts with ADR-2 in vivo. Most importantly, we have shown that A-to-I editing was not detected in substrate mRNAs isolated from the adbp-1 mutant. Thus, our results clearly indicate that ADBP-1 functions in the control of ADR-2. The importance of RNA editing by ADAR proteins was first recognized when it was found that RNA editing causes codon changes and consequent changes in protein function (Higuchi et al. 1993; Burns et al. 1997; Reenan et al. 2000). Recent studies, however, have revealed that editing of noncoding RNAs plays various roles in organisms, including modulation of splicing sites, regulation of mRNA degradation, and regulation of miRNA (Nishikura 2006; Kawahara et al. 2007). In C. elegans, several ADAR substrates have been identified by purifying inosine-containing poly(A)+ RNA molecules (Morse and Bass 1999; Morse et al. 2002). All of these editing sites were found in noncoding regions and the functions of these modifications are still unknown. A previous report (Tonkin et al. 2002) and our observations suggest that adr-2 and adbp-1 are not essential for the viability of the worm; these mutants are healthy and fertile with normal brood sizes. The function of ADR-2 in chemotactic behavior was reported previously (Tonkin et al. 2002), although we were not able to reproduce the magnitude of the defect in our chemotactic analysis. Further studies using adr-2 and adbp-1 mutants would reveal the biological roles of RNA editing in C. elegans. Transgene silencing is caused through the siRNA pathway in the RNA-editing defective mutants: We have shown that the transgene-silencing phenotype of the adbp-1 mutant depended on RNAi machinery genes. The transgene-silencing phenotype of the adr-2 mutant also depends on RNAi machinery genes (Knight and Bass 2002). These results suggest that a dsRNA intermediate is involved in the process of transgene silencing. Knight and Bass (2002) demonstrated that dsRNAs are produced from transgenes and that A-to-I editing occurs in these RNA molecules. They proposed a model in which RNA editing prevents the transgene-generated dsRNAs from causing RNAi of the transgenes in wild-type animals. In the adr-2 and adbp-1 mutants, defects in RNA editing may allow the transgene-generated dsRNA to initiate RNAi of the transgene. In this article, we have shown that adbp-1 acts cell autonomously in the hypodermis to maintain transgene expression, which is consistent with the proposed model. Our experimental result suggests that transgene silencing due to the adbp-1 mutation is most obvious with the transgenes expressed in the hypodermis and intestine. adbp-1, however, appears to be expressed not only in the hypodermis and intestine but also in other tissues, including the pharynx and some neurons where we did not observe strong transgene silencing. We do not know the reason for such a tissue-specific property of transgene silencing in adbp-1, but it might reflect the expression site of adr-2, which has not been reported yet. We have also shown that transgenes of simple arrays, which had a highly repetitive context, but not transgenes of complex arrays, were silenced. Interestingly, the expression from a complex array was suppressed in tissues in which transgene silencing was induced by a simple array containing the same gene. RNAi of transgenes appears to occur only in the cells in which the dsRNA is produced from the repetitive transgenes, although some dsRNAs can be transferred from cells to cells in C. elegans (Feinberg and Hunter 2003). The molecular mechanism of the regulation of RNA-editing activity by ADBP-1: How does ADBP-1 control the ADR-2 activity? ADBP-1 did not contain any conserved motifs. However, we found that the accumulation of ADR-2 GFP in the nucleus was reduced in the adbp-1 mutant. This result indicates that ADBP-1 supports the ADR-2 localization in the nucleus. ADBP-1 predominantly localized in the nucleus, whereas ADR-2 was distributed in both the nucleus and the cytoplasm. By binding to ADR-2, ADBP-1 may retain ADR-2 in the nucleus or support its entry into the nucleus and thereby control the deamination by ADR-2 in the nucleus. In the adbp-1 mutant, however, a certain level of ADR-2 was still observed in the nucleus, whereas no RNA editing was detected at least in the examined substrates. Therefore, we speculated that ADBP-1 may have additional functions in promoting the ADR-2 activity. The adr-2 cDNA clones, which were isolated in our yeast two-hybrid screen using ADBP-1 as the bait, encoded the N-terminal portion of ADR-2 that contains the dsRNA-binding domain. Binding of ADBP-1 to the dsRNA-binding domain may enhance the ADR-2 activity through, for example, the stabilization of the binding between dsRNA substrates and ADR-2.Because the adr-2 and adbp-1 mutants did not exhibit hypersensitivities in our feeding RNAi analysis, no antagonistic effects of RNA editing were observed in RNAi that was induced by exogenously introduced dsRNA. This may mean that these exogenously introduced dsRNAs are not edited in wild-type animals. These dsRNAs were likely to exist in the cytoplasm but not in the nucleus. Because ADBP-1 is predominantly localized in the nucleus, ADR-2 in the cytoplasm might be inactive and unable to edit these dsRNAs. One interesting possibility is that the role of ADBP-1 might be to restrict the ADR-2 activity to the nucleus and to allow the cytoplasmic RNAi processes to continue undisturbed. This may be important for the worms because in C. elegans RNAi was proven to function as an immune mechanism to RNA viruses that produce dsRNAs in the cytoplasm (Wilkins et al. 2005). On the other hand, in mammals it was reported that ADAR1 acts in the cytoplasm and indeed inhibits RNAi (Yang et al. 2005). Inhibition of RNAi by the cytoplasmic ADAR could be beneficial for organisms in which more sophisticated antiviral defense mechanisms, such as an interferon response, have developed (Nishikura 2006). The fact that we could find no ADBP-1 homologs in other organisms, including mammals, might reflect the importance of cytoplasmic RNA editing in these organisms. In this article, we have reported a crucial RNA-editing regulator, ADBP-1. ADBP-1, acting together with ADR-2, controls transgene expression by antagonizing the siRNA pathway in C. elegans. It would be interesting to examine whether ADBP-1, ADR-2, and consequent RNA editing are also involved in the regulation of the miRNA pathways. ADBP-1 was shown to regulate the nuclear localization of ADR-2. In other organisms, the spatial control of RNA-editing activities would also be important for appropriate gene regulation. Although the roles and the regulatory mechanism of RNA editing in C. elegans require further studies, our results have provided insight into gene expression control through RNAi and RNA editing. Acknowledgments We thank the Caenorhabditis elegans Genetics Center for worm strains, the Sanger Center for cosmids and YAC clones, Andy Fire for the various vectors, Bob Barstead for the two-hybrid library, Jun-ichi Miyazaki for the pCAGGS-2 expression vector, and Yuji Kohara for the cDNA clones. We also thank Tokio Tani, Isao Katsura, and Oliver Hobert for comments on the manuscript. This work was supported by Grants-in-Aid for Scientific Research (B) (18370004 to T.I.) for Young Scientists (B) (15770002 to M.F.) on Priority Areas-Molecular Brain Science (17024044 to T.I.) of the Ministry of Education, Culture, Sports, Science and Technology of Japan, as well as other grants from the Uehara Foundation (T.I.) and the Asahi Glass Foundation (T.I.). References
|
PubMed related articles
Your browsing activity is empty. Activity recording is turned off. |
|||||||||||||||||||||||
Genes Dev. 2001 Oct 15; 15(20):2654-9.
[Genes Dev. 2001]Curr Opin Genet Dev. 2006 Apr; 16(2):203-8.
[Curr Opin Genet Dev. 2006]Curr Genet. 2006 Aug; 50(2):81-99.
[Curr Genet. 2006]Curr Biol. 2003 May 13; 13(10):807-18.
[Curr Biol. 2003]Cell. 2006 Jan 27; 124(2):343-54.
[Cell. 2006]RNA. 2006 Apr; 12(4):589-97.
[RNA. 2006]Cell. 1999 Oct 15; 99(2):133-41.
[Cell. 1999]Science. 2002 May 17; 296(5571):1319-21.
[Science. 2002]Genetics. 2004 Mar; 166(3):1313-21.
[Genetics. 2004]Genes Dev. 2005 Apr 1; 19(7):782-7.
[Genes Dev. 2005]Cell. 1999 Oct 15; 99(2):123-32.
[Cell. 1999]Proc Natl Acad Sci U S A. 1989 Apr; 86(8):2647-51.
[Proc Natl Acad Sci U S A. 1989]Mol Cell. 2002 Oct; 10(4):809-17.
[Mol Cell. 2002]Nat Rev Mol Cell Biol. 2006 Dec; 7(12):919-31.
[Nat Rev Mol Cell Biol. 2006]EMBO J. 2001 Aug 1; 20(15):4243-52.
[EMBO J. 2001]Genome Biol. 2006; 7(4):R27.
[Genome Biol. 2006]Genetics. 1974 May; 77(1):71-94.
[Genetics. 1974]Nat Genet. 2001 Jun; 28(2):160-4.
[Nat Genet. 2001]EMBO J. 1991 Dec; 10(12):3959-70.
[EMBO J. 1991]Genetics. 2001 Apr; 157(4):1611-22.
[Genetics. 2001]Nature. 1998 Oct 29; 395(6705):854.
[Nature. 1998]Gene. 1991 Dec 15; 108(2):193-9.
[Gene. 1991]Neuron. 1991 Nov; 7(5):729-42.
[Neuron. 1991]Cell. 1993 Aug 13; 74(3):515-27.
[Cell. 1993]Proc Natl Acad Sci U S A. 1999 May 25; 96(11):6048-53.
[Proc Natl Acad Sci U S A. 1999]Proc Natl Acad Sci U S A. 2002 Jun 11; 99(12):7906-11.
[Proc Natl Acad Sci U S A. 2002]Mol Cell Biol. 1985 Dec; 5(12):3484-96.
[Mol Cell Biol. 1985]Dev Biol. 2002 Jun 15; 246(2):418-28.
[Dev Biol. 2002]EMBO J. 2002 Nov 15; 21(22):6025-35.
[EMBO J. 2002]Science. 2004 Jan 23; 303(5657):540-3.
[Science. 2004]Mol Cell. 2002 Oct; 10(4):809-17.
[Mol Cell. 2002]EMBO J. 2002 Nov 15; 21(22):6025-35.
[EMBO J. 2002]Science. 2005 May 20; 308(5725):1164-7.
[Science. 2005]Mol Cell. 2002 Oct; 10(4):809-17.
[Mol Cell. 2002]Mol Cell. 2002 Oct; 10(4):809-17.
[Mol Cell. 2002]EMBO J. 2002 Nov 15; 21(22):6025-35.
[EMBO J. 2002]Proc Natl Acad Sci U S A. 1999 May 25; 96(11):6048-53.
[Proc Natl Acad Sci U S A. 1999]Proc Natl Acad Sci U S A. 2002 Jun 11; 99(12):7906-11.
[Proc Natl Acad Sci U S A. 2002]J Cell Sci. 2003 May 1; 116(Pt 9):1805-18.
[J Cell Sci. 2003]Genes Dev. 1999 Nov 15; 13(22):2958-70.
[Genes Dev. 1999]Nature. 2005 Jul 28; 436(7050):593-7.
[Nature. 2005]PLoS Genet. 2006 May; 2(5):e74.
[PLoS Genet. 2006]Nat Rev Mol Cell Biol. 2006 Dec; 7(12):919-31.
[Nat Rev Mol Cell Biol. 2006]Cell. 1993 Dec 31; 75(7):1361-70.
[Cell. 1993]Nature. 1997 May 15; 387(6630):303-8.
[Nature. 1997]Neuron. 2000 Jan; 25(1):139-49.
[Neuron. 2000]Nat Rev Mol Cell Biol. 2006 Dec; 7(12):919-31.
[Nat Rev Mol Cell Biol. 2006]Science. 2007 Feb 23; 315(5815):1137-40.
[Science. 2007]Mol Cell. 2002 Oct; 10(4):809-17.
[Mol Cell. 2002]Science. 2003 Sep 12; 301(5639):1545-7.
[Science. 2003]Nature. 2005 Aug 18; 436(7053):1044-7.
[Nature. 2005]J Biol Chem. 2005 Feb 4; 280(5):3946-53.
[J Biol Chem. 2005]Nat Rev Mol Cell Biol. 2006 Dec; 7(12):919-31.
[Nat Rev Mol Cell Biol. 2006]